Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of aQIVc influenza vaccine in older adults
NCT04782323Phase 2Completed
- Sponsor
- CSL Seqirus
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of Influenza vaccine surface antigen adjuvanted with MF59 in influenza (8 arms), sponsored by CSL Seqirus. Primary endpoints: Geometric Mean Titer, Geometric Mean Ratio and 5 more. Started Apr 2021; status: completed.
02
Drugs
Influenza vaccine surface antigen adjuvanted with MF59
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04782323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782323.